Table 4.

Example experimental compounds found to ameliorate cognitive deficits in Alzheimer’s disease mouse models

Compound	Action	Behavioral Task(s)	Model(s) Tested	Reference
Ciproxifan	H3 antagonist	MWM	APP (Tg2576)	Bardgett et al., 2011 [324]
AF267B	M1 muscarinic agonist	MWM	3xTg-AD	Caccamo et al., 2006 [325]
Nicotine	nicotinic receptor agonist	RAWM MWM	chronic Aβ infusion APP/PS1	Srivareerat et al., 2011 [326] Inestrosa et al., 2013 [327]
A-582941	α7-nAChR agonist	FC, MWM	3xTg-AD	Medeiros et al., 2013 [328]
CHF5074	γ-secretase modulator	FC	APP (Tg2576)	Imbimbo et al., 2010 [329]
TAK-070	β-secretase inhibitor	MWM	APP (Tg2576)	Fukumoto et al, 2010 [330]
GRL-8234	β-secretase inhibitor	MWM	APP (Tg2576)	Chang et al., 2010 [331]
PBT2	Aβ aggregation inhibitor	MWM	APP/PS1	Adlard et al., 2008 [332]
Bexarotene	retinoid receptor X agonist	FC, MWM	APP/PS1	Cramer et al., 2012 [333]
Rolipram	PDE4 inhibitor	FC, RAWM, MWM	APP/PS1	Gong et al., 2004 [140]
Sildenafil	PDE5 inhibitor	FC, RAWM, MWM	APP/PS1	Puzzo et al., 2009 [138]
Compound 7a	PDE5 inhibitor	FC, RAWM	APP/PS1; Aβ42 intrahippocampal infusion	Fiorito et al., 2013 [33]
E64	cysteine protease inhibitor	FC, RAWM	APP/PS1	Trinchese et al., 2008 [143]
BDA-410	calpain inhibitor	FC, RAWM	APP/PS1	Trinchese et al., 2008 [143]
Trichostatin A	histone deacetylase inhibitor	FC	APP/PS1	Francis et al., 2009 [144]
MW108, MW181	p38αMAPK inhibitor	FC, RAWM	Aβ42 intrahippocampal infusion	Watterson et al., 2013 [34]